B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $104

BridgeBio Pharma

BridgeBio Pharma

BBIO

0.00

B of A Securities analyst Geoff Meacham maintains BridgeBio Pharma (NASDAQ: BBIO) with a Buy and raises the price target from $101 to $104.